Capturing the Natural Diversity of the Human Antibody Response Against Vaccinia Virus

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2010 Dec 15

PMID 21147924

Citations 18

Authors

Johan Lantto

Margit Haahr Hansen

Soren Kofoed Rasmussen

Lucilla Steinaa

Tine R Poulsen

Jackie Duggan

Mike Dennis

Irene Naylor

Linda Easterbrook

Soren Bregenholt

John Haurum

Allan Jensen

Affiliations

Soon will be listed here.

Abstract

The eradication of smallpox (variola) and the subsequent cessation of routine vaccination have left modern society vulnerable to bioterrorism employing this devastating contagious disease. The existing, licensed vaccines based on live vaccinia virus (VACV) are contraindicated for a substantial number of people, and prophylactic vaccination of large populations is not reasonable when there is little risk of exposure. Consequently, there is an emerging need to develop efficient and safe therapeutics to be used shortly before or after exposure, either alone or in combination with vaccination. We have characterized the human antibody response to smallpox vaccine (VACV Lister) in immunized volunteers and isolated a large number of VACV-specific antibodies that recognize a variety of different VACV antigens. Using this broad antibody panel, we have generated a fully human, recombinant analogue to plasma-derived vaccinia immunoglobulin (VIG), which mirrors the diversity and specificity of the human antibody immune response and offers the advantage of unlimited supply and reproducible specificity and activity. The recombinant VIG was found to display a high specific binding activity toward VACV antigens, potent in vitro VACV neutralizing activity, and a highly protective efficacy against VACV challenge in the mouse tail lesion model when given either prophylactically or therapeutically. Altogether, the results suggest that this compound has the potential to be used as an effective postexposure prophylaxis or treatment of disease caused by orthopoxviruses.

Citing Articles

Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection.

Tamir H, Noy-Porat T, Melamed S, Cherry-Mimran L, Barlev-Gross M, Alcalay R Nat Commun. 2024; 15(1):3265.

PMID: 38627363 PMC: 11021552. DOI: 10.1038/s41467-024-47328-y.

Development of a novel serological assay for the detection of mpox infection in vaccinated populations.

Yates J, Hunt D, Kulas K, Chave K, Styer L, Chakravarthi S J Med Virol. 2023; 95(10):e29134.

PMID: 37805977 PMC: 10686281. DOI: 10.1002/jmv.29134.

Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization.

Noy-Porat T, Tamir H, Alcalay R, Rosenfeld R, Epstein E, Cherry L Microbiol Spectr. 2023; :e0159823.

PMID: 37737634 PMC: 10581037. DOI: 10.1128/spectrum.01598-23.

Monkeypox and the perinatal period: what does maternal-fetal medicine need to know?.

Yan K, Tang L, Xiao F, Zhang P, Lu C, Hu L World J Pediatr. 2022; 19(3):213-223.

PMID: 36378482 PMC: 9665008. DOI: 10.1007/s12519-022-00630-5.

Human anti-smallpox long-lived memory B cells are defined by dynamic interactions in the splenic niche and long-lasting germinal center imprinting.

Chappert P, Huetz F, Espinasse M, Chatonnet F, Pannetier L, Da Silva L Immunity. 2022; 55(10):1872-1890.e9.

PMID: 36130603 PMC: 7613742. DOI: 10.1016/j.immuni.2022.08.019.

References

Klemperer N, Ward J, Evans E, Traktman P . The vaccinia virus I1 protein is essential for the assembly of mature virions. J Virol. 1997; 71(12):9285-94. PMC: 230231. DOI: 10.1128/JVI.71.12.9285-9294.1997. View

De Clercq E . Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002; 55(1):1-13. PMC: 9533828. DOI: 10.1016/s0166-3542(02)00008-6. View

Payne L . Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J Virol. 1979; 31(1):147-55. PMC: 353430. DOI: 10.1128/JVI.31.1.147-155.1979. View

He Y, Manischewitz J, Meseda C, Merchlinsky M, Vassell R, Sirota L . Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity. J Infect Dis. 2007; 196(7):1026-32. DOI: 10.1086/520936. View

Rafii-El-Idrissi Benhnia M, McCausland M, Su H, Singh K, Hoffmann J, Davies D . Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol. 2008; 82(7):3751-68. PMC: 2268460. DOI: 10.1128/JVI.02244-07. View

Grosenbach D, Hansen S, Hruby D . Identification and analysis of vaccinia virus palmitylproteins. Virology. 2000; 275(1):193-206. DOI: 10.1006/viro.2000.0522. View

Amanna I, Slifka M, Crotty S . Immunity and immunological memory following smallpox vaccination. Immunol Rev. 2006; 211:320-37. DOI: 10.1111/j.0105-2896.2006.00392.x. View

Jha P, Kotwal G . Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J Biosci. 2003; 28(3):265-71. DOI: 10.1007/BF02970146. View

Clarke L, Carbon J . A colony bank containing synthetic Col El hybrid plasmids representative of the entire E. coli genome. Cell. 1976; 9(1):91-9. DOI: 10.1016/0092-8674(76)90055-6. View

10.

Swartzman E, Miraglia S, Evangelista L, Yuan P . A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology. Anal Biochem. 1999; 271(2):143-51. DOI: 10.1006/abio.1999.4128. View

11.

Isaacs S, Kotwal G, Moss B . Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A. 1992; 89(2):628-32. PMC: 48292. DOI: 10.1073/pnas.89.2.628. View

12.

Boyle J, Haff R, Stewart R . Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrob Agents Chemother (Bethesda). 1966; 6:536-9. View

13.

Lawrence S, Lottenbach K, Newman F, Buller R, Bellone C, Chen J . Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis. 2007; 196(2):220-9. PMC: 2533043. DOI: 10.1086/518793. View

14.

Carter P . Potent antibody therapeutics by design. Nat Rev Immunol. 2006; 6(5):343-57. DOI: 10.1038/nri1837. View

15.

Lorenzo M, Galindo I, Griffiths G, Blasco R . Intracellular localization of vaccinia virus extracellular enveloped virus envelope proteins individually expressed using a Semliki Forest virus replicon. J Virol. 2000; 74(22):10535-50. PMC: 110928. DOI: 10.1128/jvi.74.22.10535-10550.2000. View

16.

Fulginiti V, Papier A, Lane J, Neff J, Henderson D . Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis. 2003; 37(2):251-71. DOI: 10.1086/375825. View

17.

Rottger S, Frischknecht F, Reckmann I, Smith G, Way M . Interactions between vaccinia virus IEV membrane proteins and their roles in IEV assembly and actin tail formation. J Virol. 1999; 73(4):2863-75. PMC: 104044. DOI: 10.1128/JVI.73.4.2863-2875.1999. View

18.

Rafii-El-Idrissi Benhnia M, McCausland M, Moyron J, Laudenslager J, Granger S, Rickert S . Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol. 2008; 83(3):1201-15. PMC: 2620895. DOI: 10.1128/JVI.01797-08. View

19.

Kovacs G, Moss B . The vaccinia virus H5R gene encodes late gene transcription factor 4: purification, cloning, and overexpression. J Virol. 1996; 70(10):6796-802. PMC: 190724. DOI: 10.1128/JVI.70.10.6796-6802.1996. View

20.

Wiberg F, Rasmussen S, Frandsen T, Rasmussen L, Tengbjerg K, Coljee V . Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng. 2006; 94(2):396-405. DOI: 10.1002/bit.20865. View